
OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …
UK cost-effectiveness watchdog NICE has rejected Takeda’s orphan bone cancer drug Mepact due to concerns over price. In its draft …

